The panel examines the evolution of atopic dermatitis (AD) treatment beyond topical steroids and calcineurin inhibitors, while evaluating the safety and efficacy of a specific topical therapy in AD management.
FDA Expands Access to Approved CAR T-Cell Therapies by Eliminating REMS
June 30th 2025The FDA has removed Risk Evaluation and Mitigation Strategies (REMS) for approved chimeric antigen receptor (CAR) T-cell therapies for hematologic malignancies, aiming to ease provider burden and expand patient access.
Read More